Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 2091-2097

  Sigsgaard, T ^a   Herrstedt, J ^a   Handberg, J ^a   Kjaer M ^a   Dombernowsky, P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; METOPIMAZINE; ONDANSETRON; PREDNISOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035300737     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.2091     Document Type: Article

References (34)

1. Effective control of CMF-related emesis with high-dose dexamethasone: Results of a double-blind crossover trial with metoclopramide and placebo
2. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy
3. Antiemetic efficacy of high-dose dexamethasone: Randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy
4. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy
5. Controlled studies of metopimazine for the treatment of nausea and vomiting
6. Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: Results of two controlled studies
7. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy
8. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study
9. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
10. Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy
11. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy
12. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer
13. Does granisetron remain effective over multiple cycles?
14. Repeated use of granisetron in patients receiving cytostatic agents
15. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group
16. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy
17. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: Evaluation of activity during three consecutive courses of chemotherapy
18. 2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy
19. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy
20. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
21. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained
22. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy
23. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis
24. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis
25. On the relationship between nausea and vomiting in patients undergoing chemotherapy
26. Protection from nausea and vomiting in cisplatin-treated patients: High-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: A study of the Italian Oncology Group for Clinical Research
27. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
28. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy
29. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
30. Dexamethasone improves the efficacy of granisetron in the first 24 H following high-dose cisplatin chemotherapy
31. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy
32. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer
33. Efficacy of ondansetron (O), methylprednisolone (M) plus metopirnazine (MPZ) in patients previously uncontrolled with dual therapy in cisplatin containing chemotherapy